



## DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC METHODS FOR THE SIMULTANEOUS ESTIMATION OF LEVOFLOXACIN AND PHENYLPROPANOLAMINE IN BULK AND PHARMACEUTICAL FORMULATIONS

Pratima Kumari Jain J\*, Anil Kumar S.M and A Satish Kumar Shetty

Department of Pharmaceutical Analysis, National College of Pharmacy (NCP), Shimoga - 577201, Karnataka, India.

\*Corresponding Author Email: [prathimajainj2007@gmail.com](mailto:prathimajainj2007@gmail.com)

### ABSTRACT

UV visible spectrophotometric method is very frequently employed in pharmaceutical analysis. It involves the measurement of the amount of ultraviolet (200-400nm) or visible (400-800nm) radiation absorbed by a substance in solution by an instrument which measures the ratio or a function of the ratio of the intensity of two beams of light in UV-Visible region. The basis of all spectrophotometric methods for multicomponent sample analysis is the property that the absorbance of a solution is the sum of absorbances of individual components or the measured absorbance is the difference between total absorbance of the solution in the sample cell and that of the solution in the reference (blank) cell.

### KEY WORDS

UV-Visible spectrophotometric methods, Absorbances

### INTRODUCTION:

UV visible spectrophotometric method is very frequently employed in pharmaceutical analysis. It involves the measurement of the amount of ultraviolet (200-400nm) or visible (400-800nm) radiation absorbed by a substance in solution by an instrument which measures the ratio or a function of the ratio of the intensity of two beams of light in UV-Visible region. The basis of all spectrophotometric methods for multicomponent sample analysis is the property that the absorbance of a solution is the sum of absorbances of individual components or the measured absorbance is the difference between total absorbance of the solution in the sample cell and that of the solution in the reference (blank) cell. The various spectrophotometric methods which are used for estimation of drug in combined dosage form include simultaneous equation method, absorbance ratio method, derivative spectrophotometry and dual wavelength method.


Levofloxacin (Fig.:1) is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. Levofloxacin acts as a bactericide. Chemically Levofloxacin is (-) -(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1, 2, 3-de] - 1, 4-benzoxazine-6-carboxylic acid hemihydrate.

Phenylpropanolamine (Fig.:2) is a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesin in cough-cold formulations. Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway potency. Chemically Phenylpropanolamine is (1S, 2R)-2-amino-1-phenylpropan-1-ol.


The combination of Levofloxacin and Phenylpropanolamine is prescribed for treating certain bacterial infections and preventing anthrax. It is quinolone antibiotic. It kills sensitive bacteria.

On literature survey, Levofloxacin alone has been estimated and simultaneous estimation in combination with other drugs has been reported. Phenylpropanolamine alone has been estimated and simultaneous estimation in combination with other drugs has been reported. It was found that no method


has been reported for the simultaneous estimation of Levofloxacin and Phenylpropanolamine in combined dosage form and no method is available in the pharmacopoeias. In the view of the need for a suitable method for routine analysis in combined formulations, attempts are being made to develop simple, precise and accurate analytical methods for simultaneous estimation of titled drugs and extend it for their determination in formulations.




**Fig 1: Chemical structure of Levofloxacin.**




**Fig. 3: Overlay Spectrum of LEVO at 287nm.**




**Fig 2: Chemical structure of Phenylpropanolamine.**




**Fig. 4: Overlay Spectrum of PPA at 256nm.**




**Fig. 5: Overlay Spectrum of Standard Mixture. Fig. 6: Overlay Spectrum of LEVO and PPA at 287nm and 256nm.**






**Fig. 7: Calibration Curve for LEVO at 287nm for Simultaneous Equation Method.**


**Fig. 8: Calibration curve for PPA at 256nm for Simultaneous Equation Method.**




**Fig. 9: Overlay of First order Derivative Spectrum of LEVO at 295nm.**



**Fig. 10: Overlay of First order Derivative Spectrum of PPA at 248nm.**



**Fig. 11: Overlay of First order Derivative Spectrum of Standard mixture.**



**Fig. 12: Overlay of First order Derivative Spectrum of LEVO & PPA at 295nm & 248nm**




Fig. 13: Calibration Curve for LEVO at 295nm by First Order Derivative.




Fig. 14: Calibration Curve for PPA at 248nm by First Order Derivative

## MATERIALS AND METHODS:

### Instrument

For UV-Visible Spectroscopy methods, Shimadzu model 1800 double beam UV-Visible Spectrophotometer with spectral band width of  $1 \pm 0.2\text{nm}$ , wavelength accuracy of  $\pm 0.3\text{nm}$  and a pair of quartz cuvettes having 1cm path length was used. Distilled water was used throughout the experimental work.

### Chemicals

Standard Levofloxacin was obtained as gift sample from micro labs, Bangalore. Standard Phenylpropanolamine was procured from yarrow chem products, Mumbai.

### Methods

#### Preparation of standard solutions

#### Preparation of standard solution of Levofloxacin (LEVO)

100mg of Levofloxacin was weighed and transferred to 100 ml volumetric flask. Drug was dissolved in 50 ml distilled water by ultra-sonication and volume was made upto the mark with distilled water to obtain finally concentration of  $1000\mu\text{g/ml}$  (stock A). From the above stock A solution 10ml of aliquot was pipetted out 100 ml volumetric flask and volume was made upto the mark with the distilled water to obtain a concentration of  $100\mu\text{g/ml}$  (stock B). From the above stock B solution further dilutions were made to get concentration range from  $3\text{--}15\mu\text{g/ml}$  for Levofloxacin.

#### Preparation of standard solution of Phenylpropanolamine (PPA)

200mg of PPA was weighed and transferred to 100 ml volumetric flask. Drug was dissolved in 70 ml distilled water by ultra-sonication and volume was made upto the mark with distilled water to obtain a concentration of  $2000\mu\text{g/ml}$  (stock A). From the above stock A solution

further dilutions were made to get concentration range from  $300\text{--}1500\mu\text{g/ml}$  for Phenylpropanolamine.

#### Preparation of sample solution

20 tablets which contains both LEVO and PPA were weighed and powdered. The tablet powder equivalent to one tablet was weighed accurately and dissolves in 70 ml distilled water and sonicated for 15mins. The solution was filtered through Whatmann filter paper No. 41, finally the volume was made up to the mark with distilled water. Further dilutions were made to bring the concentration of the drugs within the range.

#### Method of estimation

##### Method A (Simultaneous equation method)

From the above standard solution both drugs were prepared and scanned in the wavelength range of  $400\text{--}200\text{nm}$  using UV – Spectrophotometer. At  $287\text{nm}$  LEVO showed maximum absorbance and at  $256\text{nm}$  PPA shows maximum absorbance. Both drugs did not show any interference at either of the wavelength. Hence  $287\text{nm}$  and  $256\text{nm}$  for LEVO and PPA were selected as the working analytical wavelength.

$$C_x = A_{1x}y_2 - A_{2x}y_1 / a_{1x}y_2 - a_{2x}y_1$$

$$C_y = A_{2x}x_1 - A_{1x}x_2 / a_{1x}y_2 - a_{2x}y_1$$

Where,

$C_x$  = absorbance of Sample at  $287\text{nm}$

$C_y$  = absorbance of Sample at  $256\text{nm}$

$a_{1x}$  = absorptivity of Levofloxacin at  $287\text{nm}$

$a_{2x}$  = absorptivity of Levofloxacin at  $256\text{nm}$

$a_{y1}$  = absorptivity of Phenylpropanolamine at  $287\text{nm}$

$a_{y2}$  = absorptivity of Phenylpropanolamine at  $256\text{nm}$

##### Method B (First order derivative)

For the estimation of Levofloxacin and Phenylpropanolamine by first order derivative spectroscopy, zero crossing point for both drugs were obtained, and the wavelengths were selected in manner

such that at the zero crossing of one drug, the other drug should show substantial absorbance. From the first order derivative spectra of standard Levofloxacin and Phenylpropanolamine, zero crossing point of Levofloxacin was found at 287nm and zero crossing point of Phenylpropanolamine was found at 256nm and wavelength selected for their estimation was 295nm for LEVO and 248nm for PPA.

#### VALIDATION PARAMETRE:

##### Linearity

In Method A (Fig. 3 to 6) overlay spectra of both drugs and their mixtures were shown. Fig.7 and Fig.8 were shown linearity of both the drugs in their respective wavelengths. The responses of simulations equation for both drugs show linear concentration range of 3-15µg/ml and 300-1500µg/ml for LEVO and PPA

respectively. The regression equation calculated by least square method was  $y = 0.0679x + 0.0118$  and  $y = 0.0009x + 0.0028$  with correlation coefficient of both drugs was  $r^2 = 0.9995$  and  $r^2 = 0.9998$ .

In Method B (Fig. 9 to 12) overlay spectra of both drugs and their mixtures were shown. Fig.13 and Fig 14 were shown linearity of both the drugs in their respective wavelengths. The responses of first derivatives both drugs show linear concentration range of 3-15µg/ml and 300-1500µg/ml for LEVO and PPA respectively. The regression equation calculated by least square method was  $y = -0.00338x - 0.0056$  and  $y = 0.0004x + 0.0003$  with correlation coefficient of both drugs was  $r^2 = 0.9996$  and  $r^2 = 0.9996$ . Summary of validation parameters by developed methods as shown in Table no 1.

**Table 1: Summary of Validation Parameters by Developed Methods.**

| Parameter                            | Method A               |                        | Method B                |                        |
|--------------------------------------|------------------------|------------------------|-------------------------|------------------------|
|                                      | LEVO                   | PPA                    | LEVO                    | PPA                    |
| Wavelength (nm)                      | 287                    | 256                    | 295                     | 248                    |
| Linearity Range (µg/ml)              | 3-15                   | 300-1500               | 3-15                    | 300-1500               |
| Regression equation ( $y = a + bc$ ) | $y = 0.0679x + 0.0118$ | $y = 0.0009x + 0.0028$ | $y = -0.0338x - 0.0056$ | $y = 0.0004x + 0.0003$ |
| Slope (b)                            | 0.0679x                | 0.0009x                | -0.0338x                | 0.0004x                |
| Intercept (a)                        | 0.0118                 | 0.0028                 | -0.0056                 | 0.0003                 |
| Correlation Coefficient ( $r^2$ )    | 0.9995                 | 0.9998                 | 0.9996                  | 0.9996                 |
| LOD (µg/ml)                          | 0.1505                 | 8.9063                 | 0.1437                  | 12.5117                |
| LOQ (µg/ml)                          | 0.4563                 | 26.9888                | 0.4354                  | 37.9143                |

**Table 2: Statistical Validation Data for Accuracy Determination.**

| Level of % Recovery | Components | Amount present (µg/ml) | Amount of Standard drug added (µg) | Method A                    |            |        | Method B                    |            |        |
|---------------------|------------|------------------------|------------------------------------|-----------------------------|------------|--------|-----------------------------|------------|--------|
|                     |            |                        |                                    | Total amount recovered (µg) | % Recovery | RSD    | Total amount recovered (µg) | % Recovery | RSD    |
| 80%                 | LEVO       | 6                      | 4.8                                | 10.79                       | 99.90      | 0.3707 | 10.79                       | 99.90      | 0.3707 |
|                     | PPA        | 600                    | 480                                | 1079.04                     | 99.91      | 0.3725 | 1079.04                     | 99.91      | 0.3725 |
| 100%                | LEVO       | 6                      | 6                                  | 12.01                       | 100.05     | 0.1272 | 12.01                       | 100.05     | 0.1272 |
|                     | PPA        | 600                    | 600                                | 1200.02                     | 100.01     | 0.2701 | 1200.02                     | 100.01     | 0.2701 |
| 120%                | LEVO       | 6                      | 7.2                                | 13.19                       | 99.92      | 0.1911 | 13.19                       | 99.92      | 0.1911 |
|                     | PPA        | 600                    | 720                                | 1318.03                     | 99.85      | 0.1527 | 1318.03                     | 99.85      | 0.1527 |

**Table 3: Statistical Validation Data for Intra-day Precision.**

| Components         | Method A |        | Method B |        |
|--------------------|----------|--------|----------|--------|
|                    | LEVO     | PPA    | LEVO     | PPA    |
| Mean               | 99.58    | 99.94  | 100.09   | 99.98  |
| Standard Deviation | 0.3573   | 0.4455 | 0.3643   | 0.0229 |

|                             |        |        |        |        |
|-----------------------------|--------|--------|--------|--------|
| Relative Standard Deviation | 0.3587 | 0.4474 | 0.3640 | 0.0229 |
| Standard Error              | 0.1459 | 0.1819 | 0.1487 | 0.0093 |

n\*=6

**Table 4: Statistical Validation Data for Inter-day Precision.**

| Components                  | Method A |        | Method B |        |
|-----------------------------|----------|--------|----------|--------|
|                             | LEVO     | PPA    | LEVO     | PPA    |
| Mean                        | 100.17   | 99.81  | 100.06   | 100.01 |
| Standard Deviation          | 0.3582   | 0.3575 | 0.3505   | 0.0528 |
| Relative Standard Deviation | 0.3749   | 0.3755 | 0.3503   | 0.0528 |
| Standard Error              | 0.1463   | 0.1530 | 0.1431   | 0.0215 |

n\*=3

### Accuracy

Accuracy studies were done as percent recovery, it was performed by adding constant amount of the standard drug to the sample taken from formulations at levels of 80%, 100% and 120% of the test concentration. The results are tabulated in Table no 2.

### Precision

The Intraday and Interday precisions of the proposed spectrophotometric methods were determined by estimating the corresponding responses three times on the same day and on 3 different days over a period of one week for 3 different concentration and 3 replicates LEVO and PPA and the reported in terms of relative standard deviation (RSD). Statistical validation of data for Intraday and Interday precision methods as shown in Table no 3 and Table no 4.

### LOD and LOQ

The limit of detection (LOD) is defined as the lowest concentration of an analyte that an analytical process can reliably differentiate from back-ground levels. The limit of quantification (LOQ) is defined as the lowest concentration of the standard curve that can be measured with an acceptable accuracy, precision. In this study, LOD and LOQ were determined based on the standard deviation of the response and the slope of the corresponding curve using the following equations.

$LOD = 3.3 \text{ SD/Slope}$  and  $LOQ = 10 \text{ SD/Slope}$ .

Where, SD is the standard deviation of the absorbance of the sample and the slope of the related calibrations curve.

### RESULT AND DISCUSSION:

The selected drugs Levofloxacin and Phenylpropanolamine in Bulk and Formulation were estimated by using both simultaneous equation method and first order derivatives of UV spectrophotometric methods as per ICH guidelines. The methods were

validated for all validation parameters as per ICH guidelines. The linearity range in both methods for LEVO and PPA was 3-15µg/ml and 300-1500µg/ml respectively. The % RSD for intraday and inter-day precision was found to be less than 2%. The methods have been validated in assay of active pharmaceutical ingredients. The accuracy of the methods was validated by recovery studies and was found to be significant and under specification limits, with % recovery 99-100%. The assay results were found to be within the acceptable limits.

### CONCLUSION:

The developed simultaneous equation method and first order derivative methods were found to be simple, precise, specific, and accurate and can be used for routine analysis of Levofloxacin and Phenylpropanolamine. Both methods were validated as per ICH guidelines.

### ACKNOWLEDGEMENT:

Authors express sincere thanks to the principal and staff department of pharmaceutical analysis of National College of pharmacy, Shimoga for guidance, encouragement and providing laboratory facilities.

### REFERENCES:

1. Indian Pharmacopoeia. India Pharmacopoeia commission, Ghaziabad, 2010; 2: 1579, 2010; 3:1902.
2. British Pharmacopoeia. 2003; 2: 1470-71.
3. United States Pharmacopoeia. 1995: 1213-14.
4. Laurenc LB, John SL, Keith LP. Goodman and Gilman's. The pharmacological basis of therapeutics; McGraw Hill, Newyork, U.S.A. 2005: 1119-21.
5. Satoskar RS, Nirmala NR, Bhandarkar SD. Pharmacology and Pharmacotherapeutics. 2013; 215-358.
6. Tripathi KD, Essential of Medical Pharmacology.2013: 134-37.

7. [www.chemspider.com](http://www.chemspider.com).
8. <https://www.drugbank.ca/drugs/DB00397>.
9. <https://pubchem.ncbi.nlm.nih.gov/compounds>.
10. <https://en.wikipedia.org/wiki>.
11. Rupali Sanjay Joshi, Sameer Sarvesh Katiyar, Amol Trimbak Shinde, Devendra Bhaskar Zope. Estimation and Validation of Levofloxacin in bulk and eye drop formulation by UV- Spectrophotometric method. *Int J Pharm Sci Review and Res*, March- April 2012; 13(2): 80-82.
12. Tamilarasi G, DR Vetricheluon T, DR. Vekappayya D, Tharabal R, Yuvarajank. Spectrophotometric estimation of Levofloxacin hemihydrate and Cefpodoxime proxetil in tablets. *Int J Pharm and Ph Sci*, 2014; 6(4): 646-48.
13. Agrawal OD, Shirkhedkar AA, Surana SJ. Two UV – Spectrophotometric methods for simultaneous determination of Levofloxacin and Ambroxol in tablets. *Asian J Chem*, 2008; 20(3): 1957-60.
14. Rajeshree C. Kavar, Birju M. Savaliya, Arvind J. Lakkad Smita V. Soriya, Kaushik G. Kapuriya, Shital D. Faldu. Q – Absorbance Ratio Spectrophotometric Method for the Simultaneous Estimation of Cefpodoxime Proxetil and Levofloxacin Hemihydrate in their combined dosage form. *Int Bulletin Drug Res*, 2012; 2(3): 22-30.
15. Neethu Sachan, Phool Chandra, Mayank Yadav. Simple and Validation UV – Spectrophotometric method for the estimation of Levofloxacin in bulk and pharmaceutical dosage forms. *Int J Pharm Sci*, 2012; 4: 383-85.
16. Lonikar NB, Baby Sudha Lakshmi P, Mallikarjuna Gouda M. A Selective UV – Spectrophotometric analytical method to quantify the Levofloxacin in bulk sample. *E J Ph and Med Res*, 2016; 3(9): 351-53.
17. Khuhawar MY, Rind FM, Ahemeduddin Rajiper. Determination of Phenylpropanolamine in pharmaceutical preparation by second derivative spectrophotometry. *J Food and Drug Anal*, 2005; 13(4): 388-91.
18. Arun Kaura, Vika Gupta, GS Roy, Monika Kavra. Spectrophotometric determination of Chlorpheniramine maleate and Phenylpropanolamine hydrochloride in dosage forms. *Int Current Pharm J*, April. 2013; 2(5): 97-100.
19. Arun Kumar Kavra, Ravinder Sharma, Monika, Jogmohan Sharma. Simultaneous estimation of Phenylpropanolamine hydrochloride and Chlorpheniramine malate using “Simultaneous equation method (Vierodt’s method)”. *Int J Bioassay*, 2014; 3(10): 3404-07.
20. Fatma Ahmed Aly, Nohed EL-Enany, Heba Elmansi, Amany Nabil. Simultaneous determination of Cetirizine, Phenylpropanolamine and Nimesulide using third derivative spectrophotometry and high-performance liquid chromatography in pharmaceutical preparation. *Chem Central J*, 2017; 11: 99.

Received:04.08.18, Accepted: 07.09.18, Published:01.10.2018

**\*Corresponding Author:**

**Pratima Kumari Jain J\***

Email: [prathimajaini2007@gmail.com](mailto:prathimajaini2007@gmail.com)